Abstract:We explored the biomarker potential of various amyloid‐β (Aβ) isoforms in cerebrospinal fluid (CSF), quantified by liquid chromatography and tandem mass spectrometry (LC/MS–MS), to distinguish between cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD) pathology. CSF levels of Aβ1‐34, Aβ1‐37, Aβ1‐38, Aβ1‐39, Aβ1‐40, and Aβ1‐42 were decreased in CAA compared with controls. Combining all Aβ peptides effectively differentiated CAA from subjects with an AD‐CSF profile (AD‐like; area under the curve 0.84). Notably, shorter Aβ peptides were specifically reduced in CAA, not in AD‐like subjects, suggesting distinct pathological mechanisms between vascular and parenchymal Aβ accumulation. This panel could enhance CAA diagnosis. Brain amyloid‐β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular deposits in CAA mainly consist of the Aβ40 peptide, whereas Aβ42 is the predominant variant in parenchymal plaques in AD. The relevance in pathogenesis and diagnostic accuracy of various other Aβ isoforms in CAA remain understudied. We aimed to investigate the biomarker potential of various Aβ isoforms in cerebrospinal fluid (CSF) to differentiate CAA from AD pathology. We included 25 patients with probable CAA, 50 subjects with a CSF profile indicative of AD pathology (AD‐like), and 23 age‐ and sex‐matched controls. CSF levels of Aβ1‐34, Aβ1‐37, Aβ1‐38, Aβ1‐39, Aβ1‐40, and Aβ1‐42 were quantified by liquid chromatography mass spectrometry. Lower CSF levels of all six Aβ peptides were observed in CAA patients compared with controls (p = 0.0005–0.03). Except for Aβ1‐42 (p = 1.0), all peptides were decreased in CAA compared with AD‐like subjects (p = 0.007–0.03). Besides Aβ1‐42, none of the Aβ peptides were decreased in AD‐like subjects compared with controls. All Aβ peptides combined differentiated CAA from AD‐like subjects better (area under the curve [AUC] 0.84) than individual peptide levels (AUC 0.51–0.75). Without Aβ1‐42 in the model (since decreased Aβ1‐42 served as AD‐like selection criterion), the AUC was 0.78 for distinguishing CAA from AD‐like subjects. CAA patients and AD‐like subjects showed distinct disease‐specific CSF Aβ profiles. Peptides shorter than Aβ1‐42 were decreased in CAA patients, but not AD‐like subjects, which could suggest different pathological mechanisms between vascular and parenchymal Aβ accumulation. This study supports the potential use of this panel of CSF Aβ peptides to indicate presence of CAA pathology with high accuracy.

Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer's disease with APPdup and Down syndrome

Patterns and severity of vascular amyloid in Alzheimer’s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer’s disease

An APP Mutation Family Exhibiting White Matter Hyperintensities and Cortical Calcification in East China

Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer's Disease Associated with Down Syndrome

Early-Onset Cerebral Amyloid Angiopathy and Alzheimer Disease Related to an APP Locus Triplication

Delineating amyloid peptide signatures among heterogenous plaque population in Alzheimer’s Disease

Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis

Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment

Association of candidate genetic variants and circulating levels of ApoE/ApoJ with common neuroimaging features of cerebral amyloid angiopathy

Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease

Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease

Identification of Post-Translational Modifications of Aβ Peptide in Platelet Membranes from Patients with Cerebral Amyloid Angiopathy

Proteomic profiling in cerebral amyloid angiopathy reveals an overlap with CADASIL highlighting accumulation of HTRA1 and its substrates

Alzheimer’s drugs, APPlication for Down syndrome?

The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome

Chemical imaging signatures delineate heterogeneous amyloid plaque populations across the Alzheimers disease spectrum

Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline

O4‐02‐01: A Novel Role of Beta‐secretase1 (BACE1) in the Pathogenesis of Cerebral Amyloid Angiopathy (CAA)